MMP9 and precursor B-cell acute lymphoblastic leukemia: Future work will prioritize biochemical experiments to confirm drug-target (LTF/MMP9) binding, preclinical studies of their functional effects on pathways related to sepsis/relapsed B-ALL, determination of pediatric-specific pharmacokinetics profiles, and establishment of safety/tolerability in pediatric cohorts.